TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20929124
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for correcting heart failure (including digoxin, diuretics)
Study: 18761785
Drug: VAL80/HCTZ12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAL80/HCTZ12.5 mg
Study: 18761785
Drug: VAL80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAL80 mg
Study: 15834030
Drug: Sildenafil (25‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25‐100 mg)
Study: 7497559
Drug: Caffeine tablets
Normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine tablets equal to individual average daily caffeine consumption
Study: 7210779
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of diltiazem (D)
Study: 7210779
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of nifedipine (N)
Study: 11856083
Drug: Topical mononitrate
Normalized name: Thiamine Mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mononitrate hydrogel (0.2% isosorbide‐5‐mononitrate), applied twice daily for 3 weeks
Study: 11856083
Drug: Topical mononitrate
Normalized name: Thiamine Mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mononitrate hydrogel
Study: 10667099
Drug: Treatment A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: 20 MUI of penicillin G per day for 3 weeks, infused over 4 hours
Study: 10667099
Drug: Treatment B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: 30 MUI of penicillin G per day for 10 days, infused over 6 hours
Study: 7548778
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 100 mg tablet
Study: 7548778
Drug: Cefpodoxime proxetoxil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetoxil oral solution (2 mg/mL)
Study: 7548778
Drug: Cefpodoxime proxetoxil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetoxil oral solution (100 mg) with high-fat meal
Study: 475366
Drug: Cefaclor 1000
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor 1000 mg
Study: 475366
Drug: CGP 9000
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 9000 1000 mg
Study: 475366
Drug: Cephalexin 1000
Normalized name: cephalexin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 1000 mg (empty stomach)
Study: 475366
Drug: Cephalexin 1000
Normalized name: cephalexin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 1000 mg (with breakfast)
Study: 475366
Drug: Cefadroxil 1000
Normalized name: cefadroxil 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1000 mg (with breakfast)
Study: 30719873
Drug: Any spacer
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any spacer at 400 µg of salbutamol
Study: 30585458
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at Zusanli (ST 36) and Neiguan (PC 6), stimulation at 2 Hz for 30 min, twice after surgery at 6-hour intervals.
Study: 30585458
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only (control group).
Study: 27291997
Drug: Olaratumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaratumab (15 mg/kg) plus doxorubicin (75 mg/m²)
Study: 27291997
Drug: Doxorubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m²) alone
Study: 20883410
Drug: Non-tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-tamoxifen treatment
Study: 15982124
Drug: Opponent color
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opponent color pairs (e.g., the word BLUE in yellow)
Study: 15982124
Drug: Nonopponent color
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonopponent color pairs (e.g., BLUE in red)
Study: 12699401
Drug: Pranlukast 225mg
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast 225mg twice daily
Study: 12699401
Drug: Pranlukast 225mg
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast 225mg twice daily plus halved dosage of inhaled corticosteroid
Study: 9139306
Drug: Red palm
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red palm oil (RPO) supplement (2400 mu g of beta-carotene)
Study: 9139306
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (600 mu g of oral vitamin A palmitate)
Study: 3909379
Drug: Selenium (256
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (256 micrograms daily in selenium-enriched yeast)
Study: 26549704
Drug: Testosterone topical
Normalized name: testosterone topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone topical solution 2% (60 mg daily, applied to axillae)
Study: 22474059
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg rtPA
Study: 22474059
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg rtPA
Study: 22474059
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg rtPA
Study: 17578505
Drug: Calcineurin inhibitor-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitor-based immunosuppression
Study: 9792567
Drug: Flutter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutter therapy
Study: 7521992
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antithyroid drugs 6 days before radioiodine therapy
Study: 7521992
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (131I)
Study: 7521992
Drug: No antithyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithyroid drugs (control group)
Study: 2674262
Drug: Zaditen (ketotifen),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaditen (ketotifen), 1.0 mg twice daily
Study: 834152
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 3.2 g daily for 4 days
Study: 834152
Drug: Indomethacin (ID)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (ID) 300 mg daily for 4 days
Study: 834152
Drug: Acute Acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute Acetylsalicylic acid (ASA) 1.5 g
Study: 834152
Drug: Acute Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute Indomethacin (ID) 100 mg
Study: 26286203
Drug: GSK961081 (batefenterol)
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 (batefenterol) 100 μg once daily
Study: 26286203
Drug: GSK961081 (batefenterol)
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 (batefenterol) 400 μg once daily
Study: 26286203
Drug: GSK961081 (batefenterol)
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 (batefenterol) 800 μg once daily
Study: 26286203
Drug: GSK961081 (batefenterol)
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 (batefenterol) 100 μg twice daily
Study: 26286203
Drug: GSK961081 (batefenterol)
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 (batefenterol) 200 μg twice daily
Study: 26286203
Drug: GSK961081 (batefenterol)
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 (batefenterol) 400 μg twice daily
Study: 28388953
Drug: Vaccinated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated with the test product (novel combination vaccine consisting of PCV2 subunits and inactivated M. hyo strain J)
Study: 28388953
Drug: Vaccinated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated with the test product (novel combination vaccine)
Study: 26302093
Drug: Eplerenone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (100 mg/day for 1 month)
Study: 23644038
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy for 16 weeks
Study: 23644038
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment for 16 weeks
Study: 21318601
Drug: Conventional dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose-dense chemotherapy
Study: 15009002
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without cranial irradiation
Study: 3102991
Drug: GRF (growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRF (growth hormone-releasing factor)
Study: 30056615
Drug: Alternative family
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative family therapy (Control)
Study: 24374901
Drug: sorafenib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib treatment
Study: 22745145
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2x600 mg/day for 8 weeks
Study: 11893973
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 0.5% bupivacaine solution
Study: 11893973
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL normal saline (placebo)
Study: 7843752
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with successful antihypertensive therapy (category III)
Study: 7843752
Drug: Subjects who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects who remained hypertensive despite drug therapy (category IV)
Study: 2192572
Drug: Piritramide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritramide 0.1 mg/kg
Study: 17370787
Drug: Nalbuphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.1 mg/kg
Study: 350940
Drug: Tocopherol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocopherol (600 mg/day for 10 days)
Study: 30792343
Drug: ICS-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS-containing triple therapy
Study: 30792343
Drug: Single or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or double maintenance therapy
Study: 25808103
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg daily for 24 weeks
Study: 25808103
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg daily for 12 weeks
Study: 21386088
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT) using transdermal 2% testosterone gel
Study: 17542407
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (250 mg dissolved in 5 ml of water orally twice daily for 7 days)
Study: 8516521
Drug: Morphine 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.075 mg/kg i.v. every 3 hours after operation (Group A)
Study: 8516521
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral blockade 15 ml of 0.37‐5% bupivacaine with 1:200.000 adrenaline (Group B)
Study: 3121179
Drug: Lentinan (LNT)
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan (LNT) in combination with tegafur (FT), LNT dosage: 2 mg weekly, FT dosage: 600 mg/day
Study: 23299364
Drug: EZ-Blocker (EZB)
Normalized name: Jock-Eze
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EZ-Blocker (EZB)
Study: 18325720
Drug: Interviewer administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer administered dietary assessments
Study: 16579700
Drug: Adjunctive local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive local oxygen therapy
Study: 16579700
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (amoxicillin, clavulanic acid, and metronidazole) without oxygen therapy
Study: 8764115
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (amoxicillin 500 mg three times a day for 2 weeks; metronidazole 400 mg three times a day for 2 weeks; bismuth subsalicylate 262 mg four times a day for 2 weeks, followed by 262 mg every day for 4-12 months)
Study: 8764115
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (30 mg every day for 4-12 months)
Study: 8764115
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (1 g twice a day for 4-12 months)
Study: 2071126
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg clotrimazole vaginal pessary
Study: 2071126
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg fluconazole capsule
Study: 6680215
Drug: Continuous intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous intra-arterial infusion of 3-5 mg/day methotrexate to a total dose of 90-120 mg
Study: 23283029
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg daily for 1 month)
Study: 19827055
Drug: OLM+CCB combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLM+CCB combination therapy
Study: 19827055
Drug: OLM monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLM monotherapy
Study: 11874821
Drug: ATRA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA (50 mg/m(2)/d) for 3 months
Study: 524943
Drug: Dopamine 1
Normalized name: DOPamine 160 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine 1 mcg.kg‐1 body weight.minute‐1
Study: 524943
Drug: Dopamine 5
Normalized name: DOPamine 5%-100 mg/100 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine 5 mcg.kg‐1 body weight.minute‐1
Study: 6842336
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg) intravenously
Study: 22832417
Drug: 17β‐estradiol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β‐estradiol (1 mg/day for 1 month, then 2 mg/day for 2 months)
Study: 20184589
Drug: Nateglinide and
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide and Valsartan (alone and in combination)
Study: 12460134
Drug: Initiated treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiated treatment (n = 450)
Study: 7255509
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg orally, 3 times daily for 4 weeks
Study: 22181668
Drug: PVP‐iodine gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP‐iodine gel (10%)
Study: 22181668
Drug: PVP‐iodine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP‐iodine solution (10%)
Study: 17608679
Drug: Pre-embedding immunolabelling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-embedding immunolabelling procedure using monoclonal primary antibodies anti-I-CF, anti-III-CF and anti-CS.
Study: 17608679
Drug: Post-embedding immunolabelling
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-embedding immunolabelling procedure using monoclonal primary antibodies anti-I-CF, anti-III-CF and anti-CS.
Study: 20572379
Drug: Quetiapine 25
Normalized name: quetiapine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 25 mg
Study: 15029469
Drug: Quetiapine 100
Normalized name: quetiapine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 100 mg
Study: 8168806
Drug: Aspartame 15
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame 15 mg/kg/day
Study: 8168806
Drug: Aspartame 45
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame 45 mg/kg/day
Study: 31844963
Drug: Ultrasound-guided steroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided steroid wrist injections
Study: 31370873
Drug: HD-tDCS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-tDCS treatment
Study: 29192534
Drug: Intensive Language-Action
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Language-Action Therapy (ILAT)
Study: 29192534
Drug: Intensive Naming
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Naming Therapy (INT)
Study: 25907157
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy with support to taper or discontinue antidepressant treatment (MBCT-TS)
Study: 25907157
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (MBCT-TS and maintenance antidepressants)
Study: 16918640
Drug: 1.8 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg/day of konjac ceramide in milk sugar (ceramide group)
Study: 14751655
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg once daily for 6 weeks, then increased to 8 mg for an additional 6 weeks
Study: 14751655
Drug: Perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 8 mg after up-titration
Study: 9378691
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg/day during luteal phase
Study: 7901174
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of quazepam for eight weeks
Study: 7901174
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of triazolam for eight weeks
Study: 3982917
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 mg/kg body weight)
Study: 30843141
Drug: Tiotropium/Olodaterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/Olodaterol (2 μg, 5 μg, 10 μg)
Study: 29176462
Drug: Internet-delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Cognitive Behavioral Therapy (CBT)
Study: 26014476
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (vegetables packaged with cartoon characters and stickers)
Study: 22137068
Drug: Spironolactone (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (target dose 30 mg daily)
Study: 17539316
Drug: Isatis root
Normalized name: isatis root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatis root eyedrops, administered six times each day for 7 days.
Study: 17539316
Drug: Hailun eyedrops
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hailun eyedrops (levofloxacin eyedrops), administered six times each day for 7 days.
Study: 3073808
Drug: 9 months'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 months' treatment with rifampicin and isoniazid, supplemented by ethambutol for the first 8 weeks
Study: 3073808
Drug: 18 months'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 months' treatment with rifampicin and isoniazid, supplemented by ethambutol for the first 8 weeks
Study: 31832789
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous bolus of cyclosporine
Study: 21864362
Drug: Non-invasive Interactive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive Interactive Neurostimulation (NIN) therapy using the InterX device, 8 sessions over 3 post-op days
Study: 21864362
Drug: Standard hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hospital course of pain medication and rehabilitation
Study: 16581404
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128)
Study: 9415856
Drug: Parenteral naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral naloxone
Study: 7965483
Drug: Standard ORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ORS solution
Study: 7965483
Drug: Diluted ORS
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted ORS solution
Study: 7965483
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) therapy
Study: 29402422
Drug: Aspirin only
Normalized name: Aspirin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin only (ASA)
Study: 27935521
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation (5 g leucine/meal)
Study: 26333227
Drug: Shugan Yiyang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shugan Yiyang Capsules (Group A)
Study: 26333227
Drug: Oral levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levocarnitine (Group B)